This report describes a novel assay involving the polymerase chain reaction (PCR) and RNase protection for the rapid and sensitive detection of malignant lymphoid cells by nucleotide sequences within their individual rearranged gamma T-cell receptor (TCRG) genes. In this assay, clonal rearrangements are amplified from the DNA of diagnostic tumor specimens using a consensus V segment primer and a consensus J segment primer t o which the promoter for T7 RNA polymerase has been appended. The PCR product from this amplification is transcribed into a radiolabeled RNA probe. Test RNA transcribed from the opposite DNA strand is synthesized by similar methods from TCRG genes of a subsequent biopsy specimen. The test RNA is hybridized with the probe, and mismatched nucleotide sequences in the RNA hybrids are digested by RNase A. Detection of fully protected probe by means of polyacrylamide gel electrophore-IAGNOSIS O F hematolymphoid neoplasms usually D involves identification of morphologic characteristics in biopsy tissues and examination of antigen markers on malignant cells. In addition, cytogenetic studies for chromosomal abnormalities and Southern blot analysis for DNA rearrangements often provide important genotypic information distinguishing between neoplastic and benign processes. Unfortunately, even the combined application of all these methods generally fails to detect a particular malignant clone if that clone comprises less than 1% of the total cells in the population being examined.' In some instances, double-color flow cytometry appears to be capable of detecting cells of the malignant phenotype with a sensitivity as low as 1:10,000. ' Recently, application of the polymerase chain reaction (PCR) has led to procedures capable of detecting malignant cells with very high sensitivity through the amplification of DNA across breakpoints in chromosomal translocation~.',~ However, a number of considerations limit the usefulness of this approach. First, different types of translocations occur in specific forms of lymphoid neoplasia. Therefore, detection of malignant cells by this method presupposes knowledge or at least a strong suspicion of the specific form of neoplasm represented by a given case. Second, even in a particular form of lymphoid neoplasia, not all cases will contain a chromosomal translocation. Third, the position of breakpoints in one type of translocation may vary from case to case, complicating or preventing amplification of DNA across the breakpoints. Fourth, although sequences of breakpoints for different translocations are being determined at an increasing rate, many important translocation breakpoints have not yet been analyzed at the molecular level.
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This report describes a novel assay involving the polymerase chain reaction (PCR) and RNase protection for the rapid and sensitive detection of malignant lymphoid cells by nucleotide sequences within their individual rearranged gamma T-cell receptor (TCRG) genes. In this assay, clonal rearrangements are amplified from the DNA of diagnostic tumor specimens using a consensus V segment primer and a consensus J segment primer t o which the promoter for T7 RNA polymerase has been appended. The PCR product from this amplification is transcribed into a radiolabeled RNA probe. Test RNA transcribed from the opposite DNA strand is synthesized by similar methods from TCRG genes of a subsequent biopsy specimen. The test RNA is hybridized with the probe, and mismatched nucleotide sequences in the RNA hybrids are digested by RNase A. Detection of fully protected probe by means of polyacrylamide gel electrophore-
IAGNOSIS O F hematolymphoid neoplasms usually D involves identification of morphologic characteristics
in biopsy tissues and examination of antigen markers on malignant cells. In addition, cytogenetic studies for chromosomal abnormalities and Southern blot analysis for DNA rearrangements often provide important genotypic information distinguishing between neoplastic and benign processes. Unfortunately, even the combined application of all these methods generally fails to detect a particular malignant clone if that clone comprises less than 1% of the total cells in the population being examined.' In some instances, double-color flow cytometry appears to be capable of detecting cells of the malignant phenotype with a sensitivity as low as 1:10,000. ' Recently, application of the polymerase chain reaction (PCR) has led to procedures capable of detecting malignant cells with very high sensitivity through the amplification of DNA across breakpoints in chromosomal translocation~.',~ However, a number of considerations limit the usefulness of this approach. First, different types of translocations occur in specific forms of lymphoid neoplasia.
sis and autoradiography indicates the presence of malignant cells in the test specimen. Dilution experiments with DNA of cell lines from acute lymphoblastic leukemias (ALLs) show that detection of one tumor cell among 10' normal bone marrow cells is usually possible. Residual disease was also successfully detected in several cases of ALL during clinical remission, including detection in one case at the level. The procedure described here may provide a simplified and rapid method for the sensitive diagnosis and monitoring of lymphoid malignancies. This procedure should be applicable t o most antigen receptor genes, and unlike most comparable methods, requires neither analysis of nucleotide sequence nor synthesis of tumor-specific oligonucleotide probes or primers. o 1991 by The American Society of Hematology.
Therefore, detection of malignant cells by this method presupposes knowledge or at least a strong suspicion of the specific form of neoplasm represented by a given case. Second, even in a particular form of lymphoid neoplasia, not all cases will contain a chromosomal translocation. Third, the position of breakpoints in one type of translocation may vary from case to case, complicating or preventing amplification of DNA across the breakpoints. Fourth, although sequences of breakpoints for different translocations are being determined at an increasing rate, many important translocation breakpoints have not yet been analyzed at the molecular level.
An alternative kind of genotypic marker for detection of lymphoid neoplasms is the configuration of the V, D (when present), and J segments within rearranged antigen receptor genes: The markers created by these gene rearrangements, unlike chromosomal translocations, are not specific for neoplasia per se, but can serve as markers for clonal proliferation, a feature characteristic of neoplasia, and for a particular clone of neoplastic cells. V-(D)-J rearrangements have been used for some time to diagnose and monitor lymphoid neoplasia using Southern blot hybridization.' More recently, we and others have used specific DNA sequences within rearranged antigen receptor genes as markers for highly sensitive tumor detection by PCR.6-'4 The critical part of the DNA used for this purpose is the sequence of nucleotides created at the junction of rearranged segments by the combined effect of small deletions of DNA from the ends of the rearranging segments and the insertion of short stretches of random nucleotides between the segments before their joining. Our own approach has relied on the presence of conserved sequences within V and J segments, permitting the amplification of rearrangements from diagnostic tumor samples with oligonucleotide primers containing sequences complementary to these conserved sequences: After determining the sequence of DNA across the V-(D)-J junction, a tumor-specific primer complementary to the junctional sequence is constructed and used, together with a flanking, nonspecific primer, to test for Theoretically, this approach is applicable to immunoglobulin heavy chain genes and all T-cell receptor genes; although our efforts so far have focused on the gamma T-cell receptor (TCRG) gene because of the simplicity of this and the ease in finding conserved sequence primers €or the initial amplification reaction.
Major disadvantages of detecting lymphoid neoplasia using PCR primers for junctional sequences of rearranged antigen receptor genes are that the approach requires determination of the junctional region sequence and the construction of primers specific for this sequence in each case. Among the negative ramifications of these requirements are that the full procedure is rather laborious, takes significant time before results can be obtained, and calls for special and costly instrumentation. To avoid these problems, we have devised a modified approach for sensitive detection of lymphoid neoplasia based on analysis of clonatypic junctional sequences in rearranged antigen receptor genes. This procedure uses conserved region primers to generate both probe and target RNA molecules for a given tumor, followed by RNase digestion of hybrids between the probe and target to eliminate any imperfect hybrids. Analyses of two cell lines derived from acute lymphoblastic leukemias (ALLs), as well as fresh ALLs, indicate that this modified approach can generally detect lymphoid neoplasia with the same sensitivity as the earlier version, but much more rapidly and without the determination of any specific sequence information or construction of tumor-specific oligonucleotide probes or primers.
MATERIALS AND METHODS
Cell lines and bone marrow samples. SUP-B7, a cell line derived from a case of common ALL (CALL), and SUP-T1, a cell line derived from a case of T-lymphoblastic leukemia (T-ALL)" were used as sources for homogeneous malignant cells. Diagnostic bone marrow aspirates from patients B and C showed morphologic and immunophenotypic characteristics of CALL. Bone marrow from patient A showed morphologic and immunophenotypic characteristics of T-ALL. Sequences of rearranged TCRG genes involving the VyI ~ubgroup'~~'~ in these tumors have been determined previously6,7 (Tycko, unpublished results) and are shown in Table 1 . Morphologically normal bone marrow specimens were obtained from bones removed during surgical procedures and from donors for allogeneic bone marrow transplantations. All bone marrow samples were obtained with the informed consent of the donors. 
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PCR. DNA was extracted from cultured cells and bone marrow by standard methods.18 Rearranged TCRG genes were amplified from 1 to 2 pg of genomic DNA using oligonucleotide primers specific for the conserved regions within the VyI and Jy gene segments. Primers were constructed with an automated DNA synthesizer (Applied Biosystems, Foster City, CA). The sequences of the primers are given in Table 2 . The primers JyT7 and VyT7 carry at their 5' ends the sequence of the promoter for the l7 RNA polymerase.'' PCR amplifications were performed in an automated thermal cycler (Perkin Elmer Cetus, Norwalk, CT) for 25 cycles with 2.5 U Thermus aquaticus DNA polymerase (Perkin Elmer Cetus) and 50 pmol of each primer, under conditions recommended by the manufacturer. Each amplification cycle consisted of a DNA denaturation step at 94°C for 1 minute (3 minutes in the first cycle), primer annealing at 60°C for 2.5 minutes, and primer extension at 70°C for 1.5 minutes (6 minutes in the last cycle). Using these parameters, each PCR product consisted of a single band of the predicted size when analyzed by agarose gel electrophoresis. Amplifications without genomic DNA were performed alongside each set of PCR reactions to control for possible contamination with spurious templates. These reactions consistently failed to show detectable products in agarose gels.
PCR products were treated with 50 &mL proteinase K (BRL, Gaithersburg, MD) for 30 minutes at 37"C, extracted with phenol, and precipitated with 70% ethanol. One-twentieth of the PCR product in each reaction was transcribed in vitrom with 20 U of T7 RNA polymerase (Stratagene, La Jolla, CA), according to the conditions recommended by the manufacturer. Radiolabeled RNA probes were synthesized in the presence of 2 mCi/mL (800 Ci/mmol) w3*P-UTP (Dupont, NEN, Boston, MA), and adenosine triphosphate (ATP), cytosine triphosphate (CTP), and guanosine triphosphate (GTP) at a concentration of 0.4 mmovL each. Unlabeled test RNA was synthesized with all four ribonucleotides present at a concentration of 0.4 mmoVL. After transcription, the template DNA was digested with 60 U of RNase-free DNase I (Boehringer Mannheim, Germany) for 30 minutes at 37°C. Probes were separated from unincorporated radioisotype by centrifugation through Sephadex 25 (Pharmacia, Uppsala, Sweden). All transcripts were extracted with phenol and precipitated with 70% ethanol.
Radiolabeled probes were hybridized with the appropriate test RNA at a ratio of 1:lO in a total volume of 40 KL 85% formamide, 0.4 moVL NaC1; 1 mmol/L EDTA, and 40 mmoW piperazine n-n, bis: 2-ethane sulfonic acid (PIPES), pH 5.6. After denaturation for 10 minutes at 9YC, the hybridization mixtures were incubated overnight at 64°C. To digest mismatched nucleotides, 300 FL of 40 kg/mL RNase A (Boehringer Mannheim) in 0.3 mol/L NaCl, 10 mmol/L Tris-HC1 (pH 7.5), and 5 mmol/L EDTA was added to each sample? followed by incubation for 30 minutes at an empirically determined temperature of 42 to 50°C. The RNase digestion was terminated by addition of 20 JLL of 10% sodium dodecyl sulfate (SDS) and 2 )LL 50 pg/mL proteinase Kwith subsequent incubation for 15 minutes at 37°C. The digested RNA fragments were extracted with phenol, precipitated, and analyzed by electrophoresis through a 6% polyacrylamide gel 
RESULTS
The strateB' wed for the RNase protection assay to detect lymphoid neoplasia is outlined in Fig 1. DNA is amp1ified from a diapostic tumor samp1e containing a TCRG rearrangement bY PCR with primers 'Yle3 and transcript. The resulting RNA-RNA duplexes are then subjected to digestion with RNase A and analyzed by JyT7. The Vy1.3 primer anneals to a region of conserved sequence in all nine known Vy gene segments of the VyI subgr~up.'~"~ The JyT7 primer anneals to both known functional Jy segments." If the number of N nucleotides equals the number of germline nucleotides deleted during joining of the vy and Jy segments withi,, a TCRG gene rearrangement, the PCR product has a length of 281 bp, including the promoter of the ~7 RNA polymerase added at the downstream (3') end of the amplified jy segment. In vitro transcription from this template generates a tumorspecific, radiolabeled anti-sense RNA probe 18 nucleotides shorter than the template fragment. DNA from the specimen to be examinated for the presence of the tumorspecific TCRG gene rearrangement is amplified by PCR with the VyT7 and JyI7 primers. The VyT7 primer anneals to the same sequence as the Vy1.3 primer but contains the T7 promoter at its 5' end. The JyI7 primer anneals to the polyacrylamide gel electrophoresis (PAGE) under denaturing conditions.
If the tumor-specific TCRG rearrangement is present in the sample9 absence Of mismatched bases in the RNA duplex prevents RNase digestion, with the exception of the protruding 5' end Of the probe* 'resen-Of the tumorspecific TCRG rearrangement in the sample is thus indicated by a protected radioactive fragment exactly 19 nuckotides shorter than the unhybridized and undigested probe.
(The shorter length of the protected fragment relative to the undigested probe permits differentiation between protection of the probe and failure of RNase to digest single-stranded RNA sequences). If the specimen is free of any tumor-specific TCRG gene rearrangement, possible differences in Vy segments and, more likely, in the N region of rearranged TCRG genes create base mismatches in the For
org From
RNA-RNA hybrids. Unhybridized pyrimidine residues are cleaved by RNase A?' Therefore, in specimens lacking tumor-specific rearrangements, only bands smaller than those predicted for perfectly matched probe should be observed.
To test the specificity and sensitivity of strategy outlined in Fig 1, DNA extracted from the cell line SUP-B7 was logarithmically diluted into normal bone marrow DNA. One microgram of DNA from each dilution, from the normal bone marrow used to prepare the dilutions, and from four other normal bone marrow samples was amplified by PCR and transcribed into test RNA, as described above. A radiolabeled RNA probe was synthesized by PCR amplification of 1 pg undiluted SUP-B7 DNA and then by transcription of the PCR product with T7 RNA polymerase. Five percent of this probe was hybridized to one half of each test RNA preparation, followed by RNase digestion at 42°C and gel electrophoresis of the products.
The autoradiogram of the resulting gel is shown in Fig 2 . Unhybridized, undigested probe is seen as a single band corresponding to a fragment of the predicted 263 nucleotide size (lane 14), reflecting the fact that there is only one TCRG gene rearrangement containing VyI gene segments in this cell line (Table 1 ; Tycko and Sklar, unpublished results). When no test RNA was added to the hybridization mixture, the probe is digested completely (lane 13). Test RNA synthesized from pure SUP-B7 DNA yields a variety of protected fragments (lane l), the largest of which is 244 nucleotides long, corresponding to the size predicted for the probe protected from RNase digestion by perfectly matched test RNA. This band declines in intensity with progressive dilutions of SUP-B7 DNA into controlled bone marrow DNA (lanes 2 through 7) down to a dilution of lo-' (lane 6), but cannot be identified in a dilution of (lane 7) or in DNA of normal bone marrows (lanes 8 through 12). These findings are consistent with the maximum theoretical sensitivity of assay, because 1 Fg of DNA is the equivalent of 10' cells and a dilution of is therefore expected, on average, to contain only one copy of the tumor-specific TCRG gene rearrangement. The bands observed in the control bone marrow lanes correspond roughly to the length of the Vy segments within the PCR products.
Presence of these bands implies that an efficient transcription of the nonradioactive test RNA had in fact occurred. That multiple bands smaller than 244 nucleotides are observed with pure SUP-B7 test RNA indicates that RNase A may cleave even double-stranded RNA to a certain extent at the digestion temperature used for these assays.
DNA from the cell line SUP-T1 was analyzed in a manner analogous to that with which SUP-B7 was studied (Fig 3) . SUP-T1 is known to contain two TCRG gene rearrangements involving VyI gene segments (Table l) 
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composed of pure populations of tumor cells. Since some fraction of rearranged TCRG genes in diagnostic specimens can be expected to represent normal, polyclonal T cells, probe synthesized from tumor samples will often consist of RNA containing sequences different from the tumor-specific TCRG rearrangement(s). It is therefore important to demonstrate that a false-positive signal in the RNase protection assay will not result from RNA which is transcribed from heterogeneous gene rearrangements in normal lymphocytes and which hybridizes without mismatches to test RNA synthesized from the same rearrangements present in normal marrow cells. This issue was addressed in an experiment shown in Fig 4. Probes synthesized from two normal bone marrows were hybridized to test RNAs from the same marrow samples and subjected to RNase A digestion at 50°C. As expected, the probes generated from the two bone marrow specimens are composed of RNA transcripts of varying lengths (lanes 3 and 6) , and after digestion of the hybrids, no bands are detectable in the autoradiogram at the positions appropriate for full-length protection of any of the probes (lanes 1 and 4) . This result confirms the great diversity of DNA sequences in TCRG gene rearrangements of normal bone marrow.
Another issue related to the heterogeneity of most clinical samples is the potential reduction in the sensitivity of the assay if the diagnostic specimen from which the RNA probe is generated contains highly impure tumor. This problem was investigated by preparing probes from dilutions of cell line DNA in normal bone marrow DNA and performing assays with these probes on test RNA made from dilutions of the respective cell line. These analyses showed that even when the cell line DNA was diluted by a factor of tumor cells could still be detected at a concentration of 1 in a 1,000-a level at least one order of magnitude more sensitive than routinely achieved by conventional Southern blotting.
To test the applicability of the RNase protection assay for actual tumor specimens, three cases of ALL were examined. These cases had previously been analyzed by PCR amplification using tumor-specific primers complementary to junctional region sequences of rearranged TCRG genes.' The first case, from patient A, was previously demonstrated by this method to contain tumor at the level of approximately cells in a specimen of bone marrow obtained when the patient was believed to be in a complete clinical remission 1 month before a subsequent relapse (pt 5 in ref 7) . Figure 5 shows the results of assays with specimens from this case. A single band is seen in the lane containing undigested probe amplified from the original diagnostic specimen (lane 16), suggesting that only one TCRG gene rearrangement was present in the tumor. The position of fully protected probe is illustrated in lane 1, which shows the result with test RNA amplified from the original diagnostic specimen. A band in the same position can also be identified in analyses of the remission specimen (lane 9), indicating the presence of tumor despite the fact this marrow was deemed to be completely free of tumor by conventional morphologic criteria. To quantitate the amount of residual disease, analyses were performed on logarithmic dilutions of the original leukemia DNA into normal bone marrow DNA (lanes 2 through 8) . A fully protected fragment is seen only in one of two independently amplified Pt A DNA Dilutions samples of the lo-' dilution, suggesting that at this level the assay is at the Poisson limit (lanes 6 and 7) . Comparing the intensities of the bands produced from the remission and dilution samples, the fraction of leukemic cells in the remission specimen can be estimated to be about 1% of the total number of bone marrow cells. The specificity of analyses on this case was confirmed by studies on five normal bone marrows from unrelated individuals, none of which showed bands in the position corresponding to fully protected probe (lanes 10 through 14) .
The second case of ALL, from patient B, was similar to the first case, except that the level of residual disease determined previously in a presumed remission specimen, obtained 20 months before relapse, was much lower than The third case of ALL, from patient C (pt 1 in ref 7) , was selected for analysis because it contained a TCRG gene rearrangement with an N insertion consisting of only a single nucleotide-a feature that conceivably could reduce the specificity of this junctional region for the malignant clone in this case. In fact, this tumor proved to be the most difficult to assay because low amounts of false-positive signal from normal bone marrow could not be eliminated at any temperature of RNase digestion which did not greatly reduce the true positive signal from dilutions of patient C DNA. The minimum level of patient C DNA that could be detected at the lowest temperature (5OoC), which extinguished signals from normal bone marrow DNA, was lo-'.
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However, the reason for the difficulty in this case had to be due to more than the small size of the N insertion in one TCRG gene rearrangement since the tumor of patient C contains a second TCRG gene rearrangement with a six nucleotide N insertion, together with rather large deletions from the ends of the rearranged Vy and Jy segments (17 and 16 nucleotides, respectively). Gel electrophoresis of the undigested RNA probe showed that this second rearrangement was indeed transcribed, yet, like probe from the first rearrangement, this second probe also failed to detect tumor cells at dilutions of greater than
DISCUSSION
This report describes an RNase protection assay using PCR amplification of antigen receptor gene rearrangements to detect and monitor lymphoid neoplasia. Experiments with dilutions of cell line DNA into the DNA of normal, polyclonal bone marrow indicate that, applied to TCRG genes, the method is sensitive enough to detect one clonal cell in lo5 total cells-the theoretical limit of maximum sensitivity achievable with the reaction volumes routinely used. In addition, studies of ALL cases show that the method is generally as sensitive as more laborious methods involving the use of tumor-specific PCR primers for monitoring small amounts of residual disease. Altogether, from acquisition of tissue to final autoradiogram, the assay can be completed in 2 to 3 days.
Our primary motivation for developing the RNase protection assay for detecting lymphoid neoplasia was to provide a simplified and rapid alternative to other methods for highly sensitive detection of lymphoid disease lacking suitable chromosomal translocations. Potential areas of application for these techniques include monitoring of residual disease after therapy, staging of disease (in lymphoma), and detection of minute quantities of disease in particular anatomic sites (for instance, ALL in cerebrospinal fluid). Like the RNase protection assay, all comparable methods rely on the clonatypic nucleotide sequences created at the junction of rearranged gene segments in antigen receptor genes. Most of these methods require knowledge of the junctional sequence in order to construct a complementary oligonucleotide to be used either as a primer or as a This requirement implies additional effort to determine the sequence, usually by direct sequence analysis of a PCR product amplified from a diagnostic tumor specimen or by sequence analysis of the PCR product after molecular cloning in a sequencing vector. The former strategy saves time but may not be feasible if there are two clonal gene rearrangements in a case or if the malignant clone represents a small fraction of the cells within the biopsy specimen. The RNase protection assay completely circumvents sequence analysis since the probe is made directly from the diagnostic biopsy specimen. Furthermore, the number of gene rearrangements present in the diagnostic specimen is irrelevant since simultaneous analysis with more than one RNA probe is not only possible but may be desirable.
Another step required by methods using oligonucleotide primers or probes is the construction of tumor-specific oligonucleotides to match the junctional sequence. Such oligonucleotides are easily made with DNA synthesizers, but both the instrument itself and the reagents it uses are expensive. Aside from increased cost, this step carries with it the risk of errors in the sequence of the oligonucleotide synthesized, either because the sequence determined for the junctional region was inaccurate or the synthesizer was improperly programmed.
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From As mentioned above, one of the advantages of the RNase protection assay over methods using junctional sequence oligonucleotides is the ability to work with impure diagnostic biopsy specimens. Experiments in which RNA probe was made from dilutions of cell line DNA showed that even substantial contamination of clonal gene rearrangements with polyclonal rearrangements only moderately reduces the sensitivity of the RNase protection assay. This feature means that the assay could potentially be applied to primary diagnosis of lymphoid neoplasms by generating probe and test RNA from a single specimen and analyzing hybrids between the two RNA products for RNase resistance. This application is not practical for methods using junctional sequence oligonucleotides.
For reasons described above, we have begun our investigations with the RNase protection assay by studying TCRG genes. Analyses using the Southern blot technique show clonal rearrangements of this gene in the great majority of T-cell neoplasms and about two thirds of pre-B cell neoplasms.22 Recent studies using PCR amplification combined with denaturing gradient gel electrophoresis indicate that the actual frequency of lymphoid tumors with rearranged TCRG genes may be even higher.= The gene is therefore well suited for monitoring of residual disease in ALL, a neoplasm in which the administration of therapy sufficient for eradication of the tumor must be weighed against the toxicity of the treatment.
In principle, an RNase protection assay similar to that used for TCRG genes could be used for any antigen receptor gene having N insertions, as long as consensus primers can be found for accomplishing the amplification of probe and test RNAs. This requirement appears to be met by heavy chain immunoglobulin (IgH) genes'or24 in a significant number of B-cell neoplasms and by delta T-cell receptor (TCRD) genesz in many T-cell neoplasms. Both genes have already been the subjects of PCR-based methods for detecting residual disease. Rearrangements of IgH genes have been analyzed using oligonucleotides for the V-D-J junctional sequence,'@'' while TCRD gene rearrangements have been analyzed by using DNA hybridization probes produced directly from PCR products amplified from diagnostic biopsy
The latter approach, like the RNase protection assay, requires no detailed sequence information about the gene rearrangement under examination; however, a preliminary conventional Southe m blot is apparently needed in each case to identify the type of TCRD rearrangement in that case.I4 Furthermore, the method is not transferable to other antigen receptor genes and the TCRD gene is clonally rearranged in relatively fewer lymphoid tumors than the other antigen receptor genes26 (Loh and Sklar, unpublished results). Preliminary results using PCR-mediated RNase protection to detect B-cell tumors by means of rearrangements in IgH genes suggest a sensitivity similar to that found in analyses of TCRG gene rearrangements (Veelken and Shear, unpublished results).
An unexplained finding with the RNase protection assay was the reduced sensitivity of the assay applied to one case of ALL (pt C). Because both clonal TCRG gene rearrangements in the case are apparently transcribed into probe, it seems unlikely that the problem is intrinsic to the sequences of the rearranged TCRG genes. Nor is the reduced sensitivity a function of the normal bone marrow DNA used as a diluent; the same effect was found with dilutions using DNA from several different normal bone marrows. Perhaps the results in this case reflect some property of the marrow from this case, which somehow interferes with hybrid formation. Whatever accounts for this reduction in sensitivity does not apparently affect amplification of TCRG genes with a junctional region primer. In any event, the level of sensitivity achieved in this case although lower than usual, still exceeds that of conventional methods for detecting lymphoid neoplasia by at least an order of magnitude. It remains to be seen whether this case is an isolated example of reduced sensitivity. However, even if it is not, analyses of dilutions with tumor DNA on each case offers a way of determining the sensitivity of the RNase protection assay for a particular case and avoiding an inadvertent overestimation of the sensitivity in that case.
Leaving aside matters of sensitivity, cost, and speed, the overriding issue facing any new diagnostic test is the clinical usefulness of the information provided by it. Experience with tests that detect lymphoid neoplasia at the level of lo-' is sufficiently early that the answer to this question is not yet clear. Nevertheless, early indications in ALL are that patients in long-term remission and presumably cured do not have disease detectable at this level, and that at least a significant fraction of patients in remission who later relapse have detectable disease in remission bone Based on these findings, highly sensitive methods for lymphoid neoplasia seem to hold promise as a valuable tool for the management of these malignancies. A convenient and inexpensive RNase protection assay for this purpose, as described here, should increase the value of this kind of test.
